Conatus Pharmaceuticals Inc (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced financial results …
In a research report released Wednesday, Brean Capital analyst Difei Yang reiterated a Buy rating on Conatus Pharmaceuticals Inc (NASDAQ:CNAT) with a $13 price …
Brean Capital analyst Difei Yang weighed in today with her thoughts on Conatus Pharmaceuticals Inc (NASDAQ:CNAT), after the company announces the appointment of Dr. Jean Chan to …
Conatus Pharmaceuticals Inc (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, announced the completion of its …
MLV’s healthcare analyst Vernon Bernardino weighed in with an optimistic view on Conatus Pharmaceuticals Inc (NASDAQ:CNAT), after the company announced positive top-line results from its double-blind, placebo-controlled …
In a research report published Friday, MLV analyst Vernon Bernardino reiterated a Buy rating on Conatus Pharmaceuticals Inc (NASDAQ:CNAT) with a $16 price target, …
